ArticleFrontiers in oncology2026
Clinicopathological features and treatment paradigms exploration in advanced ampullary cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ampullary cancer presents unique clinical challenges due to its rarity and diagnostic complexities. Current data addressing ampullary cancer therapy are limited. This retrospective study focused on advanced disease and explored the rational therapeutic strategies especially based on histopathological subtype, which maybe provide evidence-based guidance for this understudied malignancy. Methods: We enrolled advanced ampullary cancer patients from two centers. Clinicopathological data and treatment details were collected. Treatment outcome comparisons between different chemotherapeutic regimens (gemcitabine-based vs fluorouracil-based) and different histopathologic types (Pancreaticobiliary vs Non-pancreaticobiliary) were conducted. Results: 71 patients with advanced ampullary cancer were enrolled. Elevated CA19-9 was observed in 63.4% (45/71). Postoperative metastasis occurred in 90.1% (64/71) patients. Histological subtyping was feasible in 43 patients, including 38 pancreaticobiliary, 4 intestinal, and 1 mixed subtype. All patients received first-line chemotherapy with objective response rate (ORR) of 19.7%, median progression-free survival (mPFS) of 9.6 months and median overall survival (mOS) of 33.2 months. Comparable efficacy between gemcitabine-based group (n=27) and fluorouracil-based group (n=44) (ORR 14.8% vs 22.7%, mPFS 6.67 months vs 11.20 months, mOS 26.70 months vs 38.90 months, p>0.05) were observed. Pancreatobiliary subgroup (n=38) exhibited ORR of 15.8%, median PFS of 8.33 months, and OS of 31.7 months, and 20% ORR, 9.93-month PFS, and 32.3-month OS in non-pancreatobiliary cases (n=5). Conclusions: Advanced ampullary cancer demonstrates aggressive behavior and poor chemotherapy responses. No formal statistical comparison was performed between histopathological subtypes due to the small sample size of the non-pancreatobiliary group. However, the number of patients with the pancreatobiliary-type was far greater than that with the non-pancreatobiliary-type. Due to the underrepresentation of non-pancreatobiliary-type cases, the predictive value of histopathological subtyping in advanced disease could not be adequately assessed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.